Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mayne Pharma Group ( (AU:MYX) ) has provided an update.
S&P Dow Jones Indices has announced its March 2026 quarterly rebalance of the S&P/ASX indices, reshaping membership across the S&P/ASX 20, 50, 100, 200 and 300. The changes include movements among major resource, technology, financial and industrial names, reflecting shifts in market capitalisation and liquidity across the Australian equity market.
Northern Star Resources replaces Santos in the S&P/ASX 20, while Light & Wonder and PLS Group enter the S&P/ASX 50 at the expense of Seek and Technology One, signalling evolving sector leadership. Further down the cap spectrum, multiple resource, energy transition and diversified companies are added to the S&P/ASX 100, 200 and 300, with several property, financial and healthcare names removed, affecting index-tracking portfolios and potentially trading volumes in the affected stocks.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
S&P Dow Jones Indices is a leading global index provider that designs and maintains widely tracked equity and other market benchmarks, including the S&P/ASX series that underpins index funds, ETFs and institutional mandates in the Australian market.
Average Trading Volume: 445,891
Technical Sentiment Signal: Sell
Current Market Cap: A$194.2M
For an in-depth examination of MYX stock, go to TipRanks’ Overview page.